Theriva Biologics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY September 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$24.1M | -$26.3M | -$21.4M | -$21.6M | — |
| Operating expenses | $24.1M | $26.3M | $21.4M | $21.6M | — |
| Cash from operations | -$16.7M | -$16.9M | -$19.0M | -$19.1M | — |
| Capital expenditure | $35,000 | $1,000 | $202,000 | $116,000 | — |
| Free cash flow | -$16.7M | -$16.9M | -$19.2M | -$19.2M | — |
| Share repurchases | — | — | $0 | $288,000 | — |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $77.1M |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $18.0M |
Shares outstanding 45.9M · Free float 91.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.